Suppr超能文献

达格列净急性改善 2 型糖尿病患者的内皮功能障碍,降低主动脉僵硬度和肾血管阻力指数:一项初步研究。

Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study.

机构信息

Department of Surgical, Medical, Molecular and Critical Area Pathology, I-56126, Pisa, Italy.

Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

出版信息

Cardiovasc Diabetol. 2017 Oct 23;16(1):138. doi: 10.1186/s12933-017-0621-8.

Abstract

BACKGROUND

Sodium-glucose cotransporter-2 inhibitors reduce blood pressure (BP) and renal and cardiovascular events in patients with type 2 diabetes through not fully elucidated mechanisms. Aim of this study was to investigate whether dapagliflozin is able to acutely modify systemic and renal vascular function, as well as putative mechanisms.

METHODS

Neuro-hormonal and vascular variables, together with 24 h diuresis, urinary sodium, glucose, isoprostanes and free-water clearance were assessed before and after a 2-day treatment with dapagliflozin 10 mg QD in sixteen type 2 diabetic patients; data were compared with those obtained in ten patients treated with hydrochlorothiazide 12.5 mg QD. Brachial artery endothelium-dependent and independent vasodilation (by flow-mediated dilation) and pulse wave velocity were assessed. Renal resistive index was obtained at rest and after glyceryl trinitrate administration. Differences were analysed by repeated measures ANOVA, considering treatment as between factor and time as within factor; Bonferroni post hoc comparison test was also used.

RESULTS

Dapagliflozin decreased systolic BP and induced an increase in 24 h diuresis to a similar extent of hydrochlorothiazide; 24 h urinary glucose and serum magnesium were also increased. 24 h urinary sodium and fasting blood glucose were unchanged. Oxidative stress was reduced, as by a decline in urinary isoprostanes. Flow-mediated dilation was significantly increased (2.8 ± 2.2 to 4.0 ± 2.1%, p < 0.05), and pulse-wave-velocity was reduced (10.1 ± 1.6 to 8.9 ± 1.6 m/s, p < 0.05), even after correction for mean BP. Renal resistive index was reduced (0.62 ± 0.04 to 0.59 ± 0.05, p < 0.05). These vascular modifications were not observed in hydrochlorothiazide-treated individuals.

CONCLUSIONS

An acute treatment with dapagliflozin significantly improves systemic endothelial function, arterial stiffness and renal resistive index; this effect is independent of changes in BP and occurs in the presence of stable natriuresis, suggesting a fast, direct beneficial effect on the vasculature, possibly mediated by oxidative stress reduction.

摘要

背景

钠-葡萄糖共转运蛋白 2 抑制剂通过尚未完全阐明的机制降低了 2 型糖尿病患者的血压(BP)和肾脏及心血管事件。本研究的目的是探讨达格列净是否能够急性调节全身和肾脏血管功能以及潜在的机制。

方法

16 例 2 型糖尿病患者在接受达格列净 10mgQD 治疗 2 天后,评估神经激素和血管变量,以及 24 小时尿量、尿钠、尿葡萄糖、异前列烷和自由水清除率;将数据与 10 例接受氢氯噻嗪 12.5mgQD 治疗的患者进行比较。评估肱动脉内皮依赖性和非依赖性血管舒张(通过血流介导的舒张)和脉搏波速度。在休息和给予甘油三硝酸酯后,测量肾血管阻力指数。采用重复测量方差分析,以治疗为组间因素,时间为组内因素,分析差异;还使用了 Bonferroni 事后比较检验。

结果

达格列净降低了收缩压,并诱导了与氢氯噻嗪相似程度的 24 小时尿量增加;24 小时尿葡萄糖和血清镁也增加。24 小时尿钠和空腹血糖不变。氧化应激减少,尿异前列烷下降。血流介导的舒张明显增加(2.8±2.2%至 4.0±2.1%,p<0.05),脉搏波速度降低(10.1±1.6 至 8.9±1.6m/s,p<0.05),即使校正平均血压后也是如此。肾血管阻力指数降低(0.62±0.04 至 0.59±0.05,p<0.05)。这些血管变化在氢氯噻嗪治疗的个体中未观察到。

结论

达格列净急性治疗可显著改善全身内皮功能、动脉僵硬和肾血管阻力指数;这种作用独立于血压变化,在稳定的排钠作用下发生,提示对血管有快速、直接的有益作用,可能通过降低氧化应激介导。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a238/5654086/eda3261af5ae/12933_2017_621_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验